Current approaches to drug treatment of ventricular extrasystole: results of the ETHAPRO study in the context of the use of ethacizine

Sydorova N.M.

Main
Publications
Current approaches to drug treatment of ventricular extrasystole: results of the ETHAPRO study in the context of the use of ethacizine

August 12, 2026

113

Cardiology, Rheumatology

Sydorova N.M.

УДК: 616.12-008.318

DOI: 10.32471/umj.1680-3051.279592

Keywords :

antiarrhythmic drugs,

class IС,

ethacizine,

supraventricular extrasystole,

treatment,

ventricular extrasystole

Specialities :

Cardiology, Rheumatology

Resume

Treatment of extrasystolic arrhythmia, in particular ventricular extrasystole (VE) in up-to-date arrhythmology is a problem that can be solved in several ways. Intervention and therapy are required mainly for symptomatic situations, malignant VE or conditions when the burden of VE according to 24-hour Holter monitoring of the electrocardiogram reaches a level that can lead to the development of cardiomyopathy associated with this rhythm disturbance. When establishing indications for the treatment of VE, drug therapy with antiarrhythmic drugs (AADs) is usually initiated, and in case of resistance to such therapy or a high burden of VE, catheter ablation is resorted to in order to prevent the development of cardiomyopathy. In the medical treatment of VE, class IС AADs occupy an important position, but their use is limited to conditions without severe heart pathology, accompanied by pronounced structural changes, that is, they are used in predominantly benign VE. The purpose of the article: to review the current state of the attitude to the treatment of VE, in particular the use of class IС AADs at the European level, as well as to analyze the recently published results of the ETHAPRO study on the efficacy and safety of the AAD ethacizine for VE and atrial extrasystole, which has been used for a long time in Ukraine, Latvia, and a number of other countries.

References

1. Настанова Duodecim 00064 Шлуночкова екстрасистолія (2017) guidelines.moz.gov.ua/documents/2985.
2. Настанова Duodecim 00058. Суправентрикулярна екстрасистолія (2017) guidelines.moz.gov.ua/documents/2981.
3. Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS), EP Europace, 2019, 21(6): 844–845. doi.org/10.1093/europace/euz046.
4. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC), 2022, Eur. Heart J., 43(40): 3997–4126. doi.org/10.1093/eurheartj/ehac262.
5. Gill J.S., Mehta D., Ward D.E., Camm A.J. (1992) Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality. Br. Heart J., 68: 392–397.
6. Kjekshus J., Bathen J., Orning O.M., Storstein L. (1984) A double-blind, crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes. Am. J. Cardiol., 53: 72B–78B.
7. Hamon D., Swid M.A., Rajendran P.S. et al. (2019) Premature ventricular contraction diurnal profiles predict distinct clinical characteristics and beta-blocker responses. J. Cardiovasc. Electrophysiol., 30: 836–843.
8. Primeau R., Agha A., Giorgi C. et al. (1989) Long term efficacy and toxicity of amiodarone in the treatment of refractory cardiac arrhythmias. Can. J. Cardiol., 5: 98–104.
9. Merino J.L., Tamargo J., Blomström-Lundqvist C. et al. (2025) Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 27(8): euaf076. doi.org/10.1093/europace/euaf076.
10. Fish F.A., Gillette P.C., Benson D.W.Jr. (1991) Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group. J. Am. College of Cardiol., 18(2): 356–365. doi.org/10.1016/0735-1097(91)90586-x.
11. Moretti A., Polselli M., Carbone I. et al. (2021) Takotsubo cardiomyopathy and flecainide toxicity: a case report and brief literature review. Eur. Rev. Med. Pharmacol. Sci., 25: 4069–4073.
12. Plosker G.L. (2010) Pilsicainide. Drugs, 70(4): 455–467. doi.org/10.2165/11204960-000000000-00000.
13. Гребеник М.В., Маслій С.М. (2017) Клінічний досвід фармакотерапії аритмій: фокус на етацизин — ефективність і профіль безпечності. Укр. кардіол. журн., 6: 96–103.
14. Sydorova N.M., Kolesnyk M.Y. (2025) Choosing a class IC antiarrhythmic drug for the treatment of patients without structural heart disease: clinical advantages of the most common agents (literature review). Modern Medical Technology, 17(3): 199–204. doi.org/10.14739/mmt.2025.3.336359.
15. Rosenshtraukh L.V., Shugushev K.K., Smetnev A.S. (1986) Ethacizin: a new efficacious Soviet antiarrhythmic drug of the phenothiazine group. Am. Heart J., 112(5): 932–939. doi.org/10.1016/0002-8703(86)90303-0.
16. Varon D., Rechavi M., Erez M. et al. (1993) Ethmozine and ethacizine–new antiarrhythmic drugs with defibrillating properties. J. Basic Clin. Physiol. Pharmacol., 4(4): 299–311. doi.org/10.1515/jbcpp.1993.4.4.299.
17. Kaik J., Kaik V., Kiitam M. (1992) Antiarrhythmic efficacy of ethacizine assessed by programmed electrical stimulation in patients with ventricular tachycardia. Pacing and clinical electrophysiology: PACE, 15(11 Pt 2): 2134–2137. doi.org/10.1111/j.1540-8159.1992.tb03036.x.
18. Smetnev A.S., Shugushev K.K.h, Rosenshtraukh L.V. (1987) Clinical, electrophysiologic and antiarrhythmic efficacy of moricizine HCl. Am. J. Cardiol., 60(11): 40F–44F. doi.org/10.1016/0002-9149(87)90719-3
19. Ivanov V.P. Клінічна ефективність та безпечність етацизину в пацієнтів із симптомною шлуночковою екстрасистолією без тяжких структурних уражень міокарда. Укр. кардіол. журн., 4, Sept. 2017, pp. 90–99, ucardioj.com.ua/index.php/UJC/article/view/129.
20. Сычев О.С., Романова Е.Н., Срибная О.В. (2016) Результаты клинического исследования «Оценка эффективности и безопасности препарата этацизин у больных с нарушениями ритма без выраженной органической патологии сердца». Аритмологія, 3. http://www.olfa.ua/admin/files/products/etacizin/Etacizin_Sichov.pdf.
21. Kuridze N., Etsadashvili K., Minadze E. (2024) A prospective analysis of the efficacy and safety of ethacizine during premature atrial contractions and premature ventricular contractions. Eur. Heart J., 45(Suppl. 1): ehae666.3318. doi: 10.1093/eurheartj/ehae666.3318.
22. Kuridze N., Etsadashvili K., Minadze E. (2026) Evaluation of the efficacy and safety of ethacizine in the management of premature atrial and ventricular contractions — a prospective study (ETHAPRO). Future cardiology, 22(6): 593–599. doi.org/10.1080/14796678.2026.2686702.
23. Sydorova N.M., Kolesnyk M.Y. (2025) Results of a Survey «Ethacizine evaluation for acute and chronic treatment of atrial fibrillation in real practice: Ukrainian national survey (ETERNITY)». Modern Medical Technology, 17(4): 266–278. doi.org/10.14739/mmt.2025.4.342898.
24. Sydorova N., Kolesnyk M. (2026) Results of a national survey on ethacizine for atrial fibrillation treatment in real practice as a part of a patient oriented approach. EP Europace, Volume 28, Issue Supplement_1, June 2026, euag105.105, doi.org/10.1093/europace/euag105.105.
25. Карпенко Ю.І. (2025) Флекаїнід в Україні: більше, ніж просто «усвідомлений» вибір. Укр. мед. часопис, 7(173): 26–32. DOI: 10.32471/umj.1680-3051.271750.
26. Флекаїнід у лікуванні та утриманні шлуночкових екстрасистол (2026). Укр. мед. часопис, 2(176): 31–37. DOI: 10.32471/umj.1680-3051.275046.